Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Bayer70 enrolled

Overview

The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for proficient Mismatch Repair; MSS stands for Microsatellite Stable) and whether it is safe for patients. Regorafenib works by blocking several different proteins involved in tumor growth. Nivolumab is an immunotherapy drug encouraging the body's own immune system to attack cancer cells. Both drugs have been approved, but not for how they are being used as combination therapy in this study. Brand name of regorafenib is Stivarga; brand name of nivolumab is Opdivo.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colorectal Cancer

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological or cytological confirmed advanced, metastatic, or progressive pMMR/MSS adenocarcinoma of colon or rectum * Participant must have progressed or be intolerant to prior systemic chemotherapy including fluoropyrimidines, irinotecan, oxaliplatin, anti-vascular endothelial growth factor (VEGF) therapy, and, if extended rat sarcoma viral oncogene homolog (RAS) wild type, an anti-epidermal growth factor receptor (EGFR) therapy. Exceptions may apply * Participants must have adequate organ and marrow function defined by protocol-specified laboratory tests * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Measurable disease as determined by response evaluation criteria in solid tumors (RECIST) v1.1 * Provision of recently obtained tumor tissue as per protocol specified requirement * Anticipated life expectancy greater than 3 months * Be able to swallow and absorb oral tablets Exclusion Criteria: * Participants with Mismatch repair deficient (dMMR) / microsatellite instable-high (MSI-H) colorectal cancer * Prior therapy with regorafenib, anti-programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or any form of immunotherapy to treat cancer * Presence of active central nervous system (CNS) metastases; participants with stable CNS disease or previously treated lesions are eligible for study entry * Poorly controlled hypertension, defined as a blood pressure consistently above 150/90 mmHg despite optimal medical management * Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 6 months before the start of study medication. Active pulmonary emboli or deep vein thrombosis that are significant or not adequately controlled on anticoagulation regimen * Any hemorrhage or bleeding event ≥ National Cancer Institute - Common terminology criteria for adverse events (NCI-CTCAE) Grade 3 within 28 days prior to the start of study medication * Participants with an active, known or suspected autoimmune disease * History of interstitial lung disease or pneumonitis * Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection * Other protocol defined inclusion/exclusion criteria could apply

Locations (15)

City of Hope National Medical Center

Duarte, California, United States

Rocky Mountain Cancer Centers

Denver, Colorado, United States

Miami Cancer Institute at Baptist Health South Florida

Miami, Florida, United States

Illinois Cancer Specialists

Arlington Heights, Illinois, United States

Minnesota Oncology Hematology, PA

Minneapolis, Minnesota, United States

Nebraska Cancer Specialists

Papillion, Nebraska, United States

New York Oncology Hematology. P.C.

Albany, New York, United States

Willamette Valley Cancer Institute and Research Center

Eugene, Oregon, United States

Sarah Cannon Cancer Center

Nashville, Tennessee, United States

Texas Oncology-Arlington North

Arlington, Texas, United States

...and 5 more locations

Outcomes

Primary Outcomes

Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator

ORR was defined as the percentage of participants with overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.

Time frame: Through database cut-off date of 11-NOV-2020 (Primary Completion Date) (up to 13 months)

Secondary Outcomes

Duration of Response (DOR)

DOR was defined for responders only as the time from first documentation of response (i.e. CR or PR) until disease progression or death (if death without documented disease progression). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.

Time frame: Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)

Disease Control Rate (DCR) at 8 and 16 Weeks

DCR was defined as the percentage of participants with tumor response of complete response (CR), partial response (PR) or stable disease (SD). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

Time frame: At 8, 16, 24, 32 and 40 weeks

Progression-free Survival (PFS)

PFS was the time from first dose of study medication to disease progression or death, whichever was earlier.

Time frame: Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)

Overall Survival (OS)

OS was defined as time from first dose of the study treatment to death. For patients who did not die, OS was censored at the last time point at which the survival status was known to be alive.

Time frame: Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5

TEAEs were started during treatment or within the post-treatment time window (30 days after last dose of regorafenib and 100 days after last dose of nivolumab.). TEAEs were summarized by system organ class (SOC) and preferred term, severity (based on CTCAE v5 grades). Laboratory data considered as AE were graded according to CTCAE v5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame: 30 days after last dose of regorafenib and 100 days after last dose of nivolumab until study completion (up to 30 months)